Sai Life Sciences Limited
SAILIFE
Quarterly Score
Showing the latest 12 quarterly points (newest to oldest).
Score context (latest 12 quarters)
The company does not provide specific quarterly guidance due to the lumpy nature of the CRDMO business. However, they maintain long-term aspirations of 15-20% revenue CAGR over 3-5 year blocks and a target of 28-30% EBITDA margin. They anticipate Q4 to be seasonally strong, consistent with prior years.
Quarter summary
- The company reported strong financial performance with healthy revenue growth and significant margin expansion, driven by increased business from existing customers and new collaborations.
- Management reiterated its long-term strategy focusing on integrated CRDMO services, expanding global footprint, and leveraging supply chain diversification trends.
Rationale
- Revenue grew 15% YoY to ₹440 crore in Q3 FY25, driven by both CRO (40%) and CDMO (60%) segments, indicating healthy demand and execution across services.
- EBITDA margin expanded by 110 basis points YoY to 28% in Q3 FY25, demonstrating improving operational efficiencies and operating leverage. The CFO reiterated a target of 28-30% EBITDA margin in the next four to five years.
Management reiterates confidence in achieving long-term EBITDA margin guidance of 28% to 30% over the next couple of years. FY26 capex guidance increased to INR 700 crores, indicating strong visibility and investment plans for future growth. Expects FY27 numbers to be delivered based on current visibility and capex plans.
Quarter summary
- Demonstrated strong financial performance with double-digit revenue growth and significant EBITDA expansion.
- Invested in capacity expansion, including a new dedicated Peptide Research Center, to cater to emerging therapeutic modalities.
Rationale
- Strong revenue growth of 16% YoY to INR 1,695 crores in FY25, driven by both CDMO and CRO segments, indicates healthy demand for services.
- Significant EBITDA growth of 42% YoY to INR 425 crores with margin expansion of 458 bps to 25%, moving closer to their long-term target of 28-30%, demonstrates improving operational efficiency and leverage.
While specific quantitative guidance for the full year was not provided, management reiterated the general trend of H2 being better than H1 and expressed strong confidence in sustained profitable growth driven by investments and operational efficiencies. They also indicated increased visibility on future utilization levels. The company is expanding manufacturing capacity by 80% by 2027 and doubling Process R&D capacity by next year.
Quarter summary
- The quarter showcased exceptionally strong financial performance with significant revenue and EBITDA growth, driven by robust demand across both CDMO and CRO segments.
- Significant strategic investments are being made in expanding infrastructure and capabilities, particularly in emerging modalities, to support future growth and diversify the service offering.
Rationale
- Revenue growth of 77% YoY to Rs. 496 crores, driven by a substantial 113% YoY increase in CDMO revenue (Rs. 314 crores) and 38% YoY growth in CRO revenue (Rs. 182 crores), indicating broad-based and accelerating demand.
- EBITDA surged by 305% YoY to Rs. 125 crores, with margins expanding to 25% (up 14% YoY), demonstrating significant operating leverage, scale efficiencies, and improved productivity, with management confident of reaching 28-30% margins.
Maintains confidence in meeting 15%-20% revenue growth over a 3-5 year period. Mentions that the second half of the year has historically been better than the first half. Capacity expansion plans are on track to reach 1150 KL by end of FY27. Guidance for FY27 capex will be provided later. No specific guidance on gross margins, but EBITDA target of 28%-30% is reiterated.
Quarter summary
- Delivered another strong quarter with positive momentum across Discovery, Development, and Manufacturing businesses, emphasizing trust from global innovator clients and consistent execution.
- Made meaningful progress in deepening capabilities in new technology and modalities, including peptides, flow chemistry, ADCs, and oligonucleotides, showcasing readiness for complex therapeutics.
Rationale
- Exceptional H1 FY26 revenue growth of 53% YoY (INR 1,034 crores vs. INR 675 crores), with CDMO up 72% and CRO up 28%, indicating strong execution and demand across business segments.
- Significant EBITDA growth of 101% YoY to INR 281 crores with a 650 bps margin expansion to 27%, driven by operational efficiencies and scale, demonstrating improved profitability.
Management maintained a long-term revenue CAGR guidance of 15-20% and a sustainable EBITDA margin range of 28-30%, choosing to prioritize market share and growth over-optimization of margins. Commercial pipeline visibility remains strong with 7 molecules added in 9M.
Quarter summary
- Strategic shift toward large pharma engagements is insulating the company from the global biotech funding crunch that is impacting peers.
- Aggressive multi-site expansion across Discovery (Unit 8), Peptides, ADCs, and Animal Health to diversify the technological moat beyond small molecules.
Rationale
- Exceptional financial performance with Q3 FY26 revenue growing 27% YoY (₹556 cr) and 9M FY26 revenue surging 43% YoY (₹1,590 cr), significantly outperforming the stated long-term CAGR guidance of 15-20%.
- Material margin expansion with Q3 EBITDA margins hitting 34% and 9M margins reaching 30% (up 600 bps YoY), driven by 450 bps of operating leverage on employee costs and 100 bps improvement in material margins.
Future Growth Prospects
Catalysts (next 12-24 months)
Swipe or use arrows to browse all triggers.
Capacity expansion to ~1,150 KL by FY27
• Q3 FY26 · ppt · Manufacturing capacity expansion ongoing, one production block with 225 KL capacity to be commissioned by Q2FY27; 2nd block by end of FY27
Show evidence (2)
• Q3 FY26 · ppt · Positioned to achieve 15-20% revenue CAGR over 3-5 years* & 28 - 30% EBITDA margins in the next 2-3 years
Process R&D capacity expansion and new modalities development
• Q3 FY26 · ppt · Process R&D Lab structure completed – commissioning by Sep 26
Show evidence (3)
• Q3 FY26 · ppt · Peptide process and pilot plants commissioning scheduled for Sep 26
• Q3 FY26 · ppt · Expanding capabilities in ADCs, TPDs, Peptides, CGTs, Oligos, and more.
AI-driven platforms for accelerated discovery and differentiated solutions
• Q3 FY26 · ppt · Working on building out an end-to-end AI-driven pharma services business to sustain competitive advantage
Show evidence (2)
• Q3 FY26 · ppt · AI-enabled retrosynthesis tools and DMPK automation are being used to accelerate delivery and improve outcomes
Continued growth momentum in CRO from large pharma clients
• Q3 FY26 · ppt · The CRO business continues to maintain strong growth momentum, supported by focus on increasing contributions from large pharma
Show evidence (2)
• Q2 FY26 · concall · Large pharma innovators are still in the early stages of the India supply chain build-out, and this is a process expected to be a multi-year journey ahead.
Diversified portfolio with 30 commercial molecules and 6 Phase III / pre-registration
• Q3 FY26 · ppt · Added 7 molecules to the late phase and commercial pipeline during the year, taking the total to 43 molecules
Show evidence (2)
• Q3 FY26 · ppt · 36 active molecules* -30 commercial, with 6 Phase III / pre registration
Variant perception
Non-consensus viewBase scenario realization, with growth driven primarily by capacity expansion and existing large pharma client relationships.
Upside scenario driven by faster adoption of AI/ML for discovery acceleration and successful scaling of new modalities, leading to market share gains.
Faster ramp-up of new modalities and AI integration could accelerate revenue growth beyond current projections.
Quick takeaway
Continued execution of current strategy, with capacity expansion and technology adoption driving growth.
Quick takeaway
Faster ramp-up of new modalities and AI-driven platforms contributing to accelerated revenue growth.
Quick takeaway
Slower adoption of new technologies or delays in capacity expansion impacting growth trajectory.
Quick takeaway
Continued execution of current strategy, with capacity expansion and technology adoption driving growth.
Quick takeaway
Faster ramp-up of new modalities and AI-driven platforms contributing to accelerated revenue growth.
Quick takeaway
Slower adoption of new technologies or delays in capacity expansion impacting growth trajectory.
Story of the Stock - Top Strategies
Business Segments
Community
Share your view anonymously. Comments are public and sorted newest first.
Anonymous post · 1500 characters left